BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1000 related articles for article (PubMed ID: 9647550)

  • 21. Endometrial effects of intrauterine levonorgestrel.
    Guttinger A; Critchley HO
    Contraception; 2007 Jun; 75(6 Suppl):S93-8. PubMed ID: 17531624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Application of levonorgestrel-releasing intrauterine system in early pregnancy: a case report].
    Gardyszewska A; Czajkowski K
    Ginekol Pol; 2012 Dec; 83(12):950-2. PubMed ID: 23488301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
    Mittermeier T; Farrant C; Wise MR
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunolocalization of endothelin and neutral endopeptidase in the endometrium of users of subdermally implanted levonorgestrel (Norplant).
    Marsh MM; Butt AR; Riley SC; Rogers PA; Susil B; Affandi B; Findlay JK; Salamonsen LA
    Hum Reprod; 1995 Oct; 10(10):2584-9. PubMed ID: 8567775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in women.
    Morison NB; Zhang J; Kaitu'u-Lino TJ; Fraser IS; Salamonsen LA
    Reproduction; 2007 Jan; 133(1):309-21. PubMed ID: 17244756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
    Luukkainen T; Allonen H; Haukkamaa M; Holma P; Pyörälä T; Terho J; Toivonen J; Batar I; Lampe L; Andersson K
    Contraception; 1987 Aug; 36(2):169-79. PubMed ID: 3123132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
    Wildemeersch D; Janssens D; Weyers S
    Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of intrauterine levonorgestrel use on the expression of c-JUN, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium.
    Salmi A; Pakarinen P; Peltola AM; Rutanen EM
    Mol Hum Reprod; 1998 Dec; 4(12):1110-5. PubMed ID: 9872360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential elevation of matrix metalloproteinase expression in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time.
    Labied S; Galant C; Nisolle M; Ravet S; Munaut C; Marbaix E; Foidart JM; Frankenne F
    Hum Reprod; 2009 Jan; 24(1):113-21. PubMed ID: 18812421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mRNA expression of insulin-like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-1 are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system.
    Rutanen EM; Salmi A; Nyman T
    Mol Hum Reprod; 1997 Sep; 3(9):749-54. PubMed ID: 9357999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.
    Papaikonomou K; Kopp Kallner H; Söderdahl F; Gemzell-Danielsson K
    Hum Reprod; 2018 Nov; 33(11):2002-2009. PubMed ID: 30295731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The levonorgestrel intrauterine system: the benefits of reduced bleeding.
    Cameron IT
    Eur J Contracept Reprod Health Care; 2001 Jan; 6 Suppl 1():27-32. PubMed ID: 11336431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical staining of von Willebrand factor in endometrium of women during the first year of Norplant implants use.
    Au CL; Affandi B; Rogers PA
    Contraception; 1994 Nov; 50(5):477-89. PubMed ID: 7859456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system.
    Fong YF; Singh K
    Contraception; 1999 Sep; 60(3):173-5. PubMed ID: 10640162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endometrial morphological changes in IUD users: a review.
    Sheppard BL
    Contraception; 1987 Jul; 36(1):1-10. PubMed ID: 3117492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen.
    Philip S; Taylor AH; Konje JC; Habiba M
    J Obstet Gynaecol; 2019 Nov; 39(8):1117-1122. PubMed ID: 31195902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between endometrial histology, microvascular density and calibre, matrix metalloproteinase-3 and bleeding pattern in women using a levonorgestrel-releasing intrauterine system.
    Oliveira-Ribeiro M; Petta CA; De Angelo Andrade LA; Bahamondes L; Hidalgo MM
    Hum Reprod; 2004 Aug; 19(8):1778-84. PubMed ID: 15192067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis.
    Laoag-Fernandez JB; Maruo T; Pakarinen P; Spitz IM; Johansson E
    Hum Reprod; 2003 Apr; 18(4):694-9. PubMed ID: 12660258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.